Literature DB >> 21167555

Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant.

Robert Anthony Smith1, Ali Salajegheh, Stephen Weinstein, Mohammad Nassiri, Alfred King-Yin Lam.   

Abstract

Mutation of the BRAF gene is common in thyroid cancer. Follicular variant of papillary thyroid carcinoma is a variant of papillary thyroid carcinoma that has created continuous diagnostic controversies among pathologists. The aims of this study are to (1) investigate whether follicular variant of papillary thyroid carcinoma has a different pattern of BRAF mutation than conventional papillary thyroid carcinoma in a large cohort of patients with typical features of follicular variant of papillary thyroid carcinoma and (2) to study the relationship of clinicopathological features of papillary thyroid carcinomas with BRAF mutation. Tissue blocks from 76 patients with diagnostic features of papillary thyroid carcinomas (40 with conventional type and 36 with follicular variant) were included in the study. From these, DNA was extracted and BRAF V600E mutations were detected by polymerase chain reaction followed by restriction enzyme digestion and sequencing of exon 15. Analysis of the data indicated that BRAF V600E mutation is significantly more common in conventional papillary thyroid carcinoma (58% versus 31%, P = .022). Furthermore, the mutation was often noted in female patients (P = .017), in high-stage cancers (P = .034), and in tumors with mild lymphocytic thyroiditis (P = .006). We concluded that follicular variant of papillary thyroid carcinoma differs from conventional papillary thyroid carcinoma in the rate of BRAF mutation. The results of this study add further information indicating that mutations in BRAF play a role in thyroid cancer development and progression.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167555     DOI: 10.1016/j.humpath.2009.09.023

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  20 in total

1.  Multifocal fibrosing thyroiditis and its association with papillary thyroid carcinoma using BRAF pyrosequencing.

Authors:  Renee Frank; Zubair W Baloch; Caren Gentile; Christopher D Watt; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

2.  BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma.

Authors:  Ji Young Park; Wook Youn Kim; Tae Sook Hwang; Sang Sook Lee; Hyunkyung Kim; Hye Seung Han; So Dug Lim; Wan Seop Kim; Young Bum Yoo; Kyoung Sik Park
Journal:  Endocr Pathol       Date:  2013-06       Impact factor: 3.943

3.  Thyroid cancers with benign-looking sonographic features have different lymph node metastatic risk and histologic subtypes according to nodule size.

Authors:  Dong Yeob Shin; Young Ki Lee; Kwang Joon Kim; Kyeong Hye Park; Sena Hwang; Se Hee Park; Eun-Kyung Kim; Hyeong Ju Kwon; Eun Jig Lee
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

Review 4.  The association between BRAF (V600E) mutation and pathological features in PTC.

Authors:  Xin Liu; Kangkang Yan; Xuejun Lin; Longyu Zhao; Wenxiu An; Chunpeng Wang; Xiaodong Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-04       Impact factor: 2.503

5.  Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

Authors:  Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; Young Kee Shong; Tae Yong Kim; David Viola; Rossella Elisei; Bela Bendlová; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Roderick Clifton-Bligh; Giovanni Tallini; Elizabeth H Holt; Vlasta Sýkorová
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

6.  Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients.

Authors:  Mi Kyung Shin; Jeong Won Kim; Soo Kee Min; Dong Jin Lee; Jin Hwan Kim; Seung Chul Lee; Bong Wha Chung; Young Su Ju
Journal:  Oncol Lett       Date:  2015-06-22       Impact factor: 2.967

7.  Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.

Authors:  Md Atiqur Rahman; Ali Salajegheh; Robert Anthony Smith; Alfred King-Yin Lam
Journal:  Endocrine       Date:  2016-05-14       Impact factor: 3.633

8.  Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.

Authors:  Xiaoguang Shi; Rengyun Liu; Fulvio Basolo; Riccardo Giannini; Xiaopei Shen; Di Teng; Haixia Guan; Zhongyan Shan; Weiping Teng; Thomas J Musholt; Khawla Al-Kuraya; Laura Fugazzola; Carla Colombo; Electron Kebebew; Barbara Jarzab; Agnieszka Czarniecka; Bela Bendlova; Vlasta Sykorova; Manuel Sobrinho-Simões; Paula Soares; Young Kee Shong; Tae Yong Kim; Sonia Cheng; Sylvia L Asa; David Viola; Rossella Elisei; Linwah Yip; Caterina Mian; Federica Vianello; Yangang Wang; Shihua Zhao; Gisele Oler; Janete M Cerutti; Efisio Puxeddu; Shen Qu; Qing Wei; Huixiong Xu; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hongyu Yu; Giovanni Tallini; Elizabeth H Holt; Vasily Vasko; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2015-11-03       Impact factor: 5.958

9.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Authors:  Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; David Viola; Rossella Elisei; Bela Bendlova; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Ralph P Tufano; Sara I Pai; Martha A Zeiger; William H Westra; Douglas P Clark; Roderick Clifton-Bligh; David Sidransky; Paul W Ladenson; Vlasta Sykorova
Journal:  JAMA       Date:  2013-04-10       Impact factor: 56.272

Review 10.  Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.

Authors:  Ichiro Abe; Alfred King-Yin Lam
Journal:  Curr Oncol Rep       Date:  2021-02-13       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.